This invention identifies two polymorphic genetic markers in the SLCO1B3 (formerly SLC21A8) gene, called 334T>G and 699G>A, that can be measured in genomic DNA obtained from a blood sample to predict survival from diagnosis of prostate cancer in that individual patient.
Researchers at the National Cancer Institute’s Biopharmaceutical Development Program recently developed massively parallel sequencing methods for virus-derived therapeutics such as viral vaccines and oncolytic immunotherapies, for which the NCI seeks licensees or co-development collaborations.
NCI scientists developed a method that uses urine samples to detect early-stage cancers and that could supplement low-dose computed tomography (LD-CT) for early-stage cancer detection, and significantly decrease expensive false negative/false positive results. The NCI seeks co-developers or licensees to commercialize this technology.
Researchers at the National Cancer Institute (NCI) developed a multiplex assay to determine the efficacy of apoptosis-related drugs targeting the Bcl2 family of proteins or aid in the selection of cancer patients likely to respond. The NCI seeks partners for co-development or licensees for commercialization of novel immunoassays for determining or predicting patient response to cancer therapy.
The invention is a novel methodology for predicting a mantle cell lymphoma (MCL) cancer patient’s survival prognosis. This information is important in helping determine the best course of treatment for the patient.
The National Eye Institute seeks research and co-development partners and/or licensees to: (1) advance the production and uses of the new RNA preparation method; (2) manufacture reagent kits for testing in patients with suspected COVID-19 and other DNA/RNA viruses, and (3) manufacture reagent kits for patient biomarker profiles and inherited disease diagnostics.
